Spark Biomedical Receives Global Recognition for Women’s Health Innovation
Spark Biomedical, parent company of OhmBody, has been selected as one of only 13 organizations worldwide to receive funding from Wellcome Leap’s “The Missed Vital Sign” initiative, which supports groundbreaking advances in women’s health. The award recognizes Spark’s innovative transcutaneous auricular neurostimulation (tAN) platform, a noninvasive, non-pharmaceutical therapy that engages the nervous system to enhance platelet function and reduce heavy menstrual bleeding (HMB). This milestone underscores Spark Biomedical’s commitment to transforming women’s healthcare through cutting-edge neurotechnology. 
Spark Biomedical Receives Global Recognition for Women’s Health Innovation